[{"name": "Langseth-Perinealusetalc-2008", "features": [{"name": "Conclusion", "value": "Perineal use of talc may be a possible carcinogen for ovarian cancer; There is strong evidence indicating a possible association between talc use in the perineal region and ovarian cancer.; The epidemiological evidence suggests that use of cosmetic talc in the perineal area may be associated with ovarian cancer risk. The mechanism of carcinogenicity may be related to inflammation. The IARC has classified this use of talc as possibly carcinogenic to human beings (group 2B)."}, {"name": "No. of Subjects", "value": "112-824 ovarian cancer cases; At least 188 cases were included in the eight population-based case-control studies."}, {"name": "Relative Risk", "value": "odds ratios ranging from 1.1 to 3.9; Each of the eight selected studies indicated a 30-60% increase in risk of ovarian cancer among body powder users."}, {"name": "Length of Follow", "value": "Some studies tried to assess exposure-response associations, in terms of frequency of use or length of use in years but found no clear trend."}, {"name": "Type of Studies", "value": "population-based case control studies and hospital-based case control studies"}, {"name": "Environmental Exposures", "value": "Talc and Asbestos"}, {"name": "Length of Follow-up", "value": "Not specified."}, {"name": "Methodological Factors", "value": "Recall bias should be considered in case-control studies, but it is unlikely to fully explain the consistent findings."}, {"name": "Experimental Research", "value": "Experimental research is needed to better characterise deposition, retention and clearance of talc to evaluate the ovarian carcinogenicity of talc."}, {"name": "Assessment of Exposure", "value": "Future studies, irrespective of study design, devote some effort to better assessment of exposure. The use of body powders should be assessed both in terms of calendar time and age of the subject. Subjects should be asked about lifetime use, including age at initial use (infancy, childhood, teenager years, adulthood), age at which they stopped using such powders, gaps in the lifetime period of use and frequency and nature of use (daily, during certain seasons of the year, only while menstruating). Another important question is whether the use of body powder was before or after tubai ligation or hysterectomy."}, {"name": "Variation of Evidence in Different Countries", "value": "While there has been some efforts to measure the degree of use, these have mainly been measured simply as the reported years of use. It is possible that the ostensible lack of exposure response trends is the result of crudeness of the exposure metric used. Therefore, it is important that future studies seek evidence in other countries where perineal use of talc has been common."}, {"name": "Risk Factors", "value": "talc use, personal and environmental characteristics, mineral fiber exposure, hair dyes, analgesics, tranquilizers, perineal talc application, tubal sterilization, hysterectomy, age at initial use of body powder, exposure assessments, dose response associations, inflammation of the ovarian epithelium, hereditary breast and ovarian cancer, estrogens"}, {"name": "Sources of Funding", "value": "Cancer Registry of Norway"}, {"name": "Acknowledgements", "value": "The work reported in this paper was initiated while SH, JS and EW were part of an IARC Monographs Working Group of the International Agency for Research on Cancer, Lyon, France."}, {"name": "No. of subjects", "value": ""}]}, {"name": "Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California", "features": [{"name": "Conclusion", "value": "This study provides some support for the hypothesis that perineal talc use is associated with an increased risk of EOC.; The paper does not provide any explicit conclusion.; Final models included terms for age, race/ethnicity, oral contraceptive use and breast-feeding; Ever use of talcum powder in the genital area was associated with a 37% elevation in risk of EOC, which was statistically significant; Perineal talcum powder use is associated with an increased risk of epithelial ovarian cancer.; Talc use is associated with an increased risk of EOC among all ethnic groups, but the risk varies by histologic subtype. There is no clear dose-response relationship based on duration or cumulative use. Cornstarch use does not appear to be related to EOC, but the number of participants using cornstarch was small. Manufacturers voluntary guidelines have prevented asbestos contamination in talc products since 1976.; Increased risk of EOC with first use of talc after age 20 compared to first use at younger ages. Increased EOC risk with talc exposure during ovulatory periods and in parous reproductive tracts.; Research has provided little biologic or experimental evidence to support a relationship between talcum powder use and ovarian cancer risk. However, given the suggestive though uncertain role of talcum powder and EOC found in epidemiologic studies, including the present study, users should exercise prudence in reducing or eliminating use.; The paper does not provide an explicit conclusion."}, {"name": "No. of subjects", "value": "256 cases and 1,122 controls; 256 cases and 1,122 controls; Cases: 256, Controls: 1,122"}, {"name": "Relative risk", "value": "OR for ever use of talc was 1.37 (CI 1.02-1.85); 37% elevation in risk of EOC; Multivariate-adjusted OR: 1.51-2.56"}, {"name": "Length of follow", "value": "Not specified; 2000-2001"}, {"name": "Demographic factors", "value": "Included in the interview"}, {"name": "Exogenous hormone use", "value": "Included in the interview"}, {"name": "Tubal ligation", "value": "TL modified the effect of talc on EOC such that women with TL had an OR of 0.88 (CI 0.46-1.68) associated with perineal talc use, whereas women with no TL had an OR of 1.54 (CI 1.10-2.16)"}, {"name": "No. of Subjects", "value": "635 cases that met the study criteria; 1,122 completed control interviews; 256; The paper does not provide information on the number of subjects."}, {"name": "Relative Risk", "value": "1.54; OR (cid:1) 1.37; CI (cid:1) 1.02\u20131.85; The paper does not provide information on relative risk."}, {"name": "Length of Follow-up", "value": ""}, {"name": "Geographic Location", "value": "The study was conducted in 22 counties of Central California."}, {"name": "Ethnic Diversity", "value": "The Central Valley of California is a very ethnically diverse area in which many counties are over 40% Hispanic."}, {"name": "Cancer Registries", "value": "Two population-based cancer registries, the Cancer Registry of Central California (CRCC) in Fresno and the Cancer Surveillance Program (CSP), Region 3, in Sacramento, have monitored cancer incidence in the Central Valley of California continuously since 1988."}, {"name": "Histological Subtypes", "value": "57% of the case series were serous adenocarcinomas, mucinous and endometrioid each comprised 14% of the EOC cases, clear cell and other/unclassified histologies made up the remaining 5% and 11%, respectively"}, {"name": "Response Fraction", "value": "40% among all cases identified, 57% for total identified eligible controls"}, {"name": "Demographic Characteristics", "value": "Controls were less likely to have finished high school but more likely to have an education beyond high school, a somewhat larger proportion of the case series were single (12.5%) compared to the control series (10.0%), control women were more likely to have been born outside of the United States (16.8%) than were cases (12.9%)"}, {"name": "Education level", "value": "Talc use was also associated with a higher education level"}, {"name": "Age of subjects", "value": "Case women using talc were slightly older at interview than controls"}, {"name": "Ethnicity", "value": "White non-Hispanic women were more likely to use talc than their Hispanic counterparts"}, {"name": "Histologic subtype", "value": "Serous, Mucinous, Endometrioid, Clear cell, Other epithelial, Serous borderline, Mucinous borderline"}, {"name": "Timing of talc use", "value": "Year of first use, Age at first use, First use before or after first birth, Years since last use"}, {"name": "Length of Follow", "value": "unknown; The paper does not provide information on the length of follow-up."}, {"name": "Interaction Coefficient", "value": "Not Statistically Significant"}, {"name": "Exogenous Hormone Use", "value": "Not a Modifier"}, {"name": "BMI", "value": "Not a Modifier"}, {"name": "Frequency of Talc Use", "value": "38.2% in younger group and 36.4% in older group for controls. Talc exposure was 43.8% for ever married cases versus 34.4% for never married cases. Frequency of use was similar between ever married and never married controls (37.2% and 36.0%, respectively)."}, {"name": "Ethnicity and Talc Use", "value": "Talc use was higher in white non-Hispanics compared to Hispanics. There was much greater use of talc among those born in the United States versus those born outside it."}, {"name": "Education Level and Talc Use", "value": "As in other studies, talc use increased with education level, although one earlier study reported the opposite finding."}, {"name": "Age at first use", "value": "Increased risk of EOC with first use of talc after age 20 compared to first use at younger ages."}, {"name": "Perineal use", "value": "Significant increase in EOC risk if perineal talc use occurred in the last 6 months."}, {"name": "Oral contraceptives", "value": "Elevated risks were found in those talcum powder users that never used OCs in this study, suggesting uninterrupted ovulation with associated formation of inclusion cysts may enhance the impact that talcum powder may have on ovarian carcinogenesis."}, {"name": "BMI Effect", "value": ""}, {"name": "OC use", "value": ""}, {"name": "Limitations", "value": "The sample size was relatively small and the response fraction lower than ideal. Recall bias has also been implicated as a limitation in studies of talc and ovarian cancer. The present analysis was also limited due to our inability to exclude use during nonovulatory periods and posttubal ligation or hysterectomy, nor were we able to differentiate between various formulations."}, {"name": "Type of Exposure", "value": "The paper discusses perineal powder exposure as a potential risk factor for ovarian cancer."}, {"name": "Types of Studies", "value": "The paper mentions retrospective studies and case-control studies."}]}, {"name": "Perineal talc exposure and risk of ovarian carcinoma", "features": [{"name": "Conclusion", "value": "This investigation supports previous contentions that exposure to talc may increase risk of ovarian carcinoma. Questionable trends in duration and frequency of exposure suggest that further studies may be needed to clarify the role of talc in the etiology of this disease.; Further investigation needed for talc exposure in ovarian carcinoma.; Regular talc exposure is associated with an increased risk of ovarian carcinoma.; Possible association between talc exposure and ovarian carcinoma; Talc exposure increases the risk of ovarian carcinoma.; Further studies are needed to clarify the role of talc in the etiology of ovarian carcinoma.; No conclusion mentioned in the text"}, {"name": "No. of subjects", "value": "450 patients with borderline and invasive ovarian carcinoma and 564 population controls in metropolitan Toronto and nearby areas of southern Ontario, Canada"}, {"name": "Relative risk", "value": "odds ratio [OR] 1.42, 95% confidence interval [CI] 1.08\u20131.86"}, {"name": "Length of follow up", "value": ""}, {"name": "Patient demographics", "value": "Subjects were from metropolitan Toronto and nearby areas of southern Ontario, Canada"}, {"name": "No. of Subjects", "value": "450 cases and 564 controls.; Not Specified; Not mentioned in the text"}, {"name": "Relative Risk", "value": "Decreasing risk with increasing oral contraceptive use and lactation per pregnancy.; 1.42 (95% CI 1.08-1.86); 1.513; OR 1.42, 95% CI 1.08 \u2013 1.86; Not mentioned in the text"}, {"name": "Length of Follow-up", "value": "Follow-up period not specified.; Not Specified; Not mentioned in the text"}, {"name": "Method of Analysis", "value": "Multiple unconditional logistic regression with SAS statistical package."}, {"name": "Years of Oral Contraceptive Use", "value": "12.3"}, {"name": "Ever had Tubal Ligation", "value": "18.0%"}, {"name": "Mother/Sister with Breast or Ovarian Carcinoma", "value": "13.8%"}, {"name": "Length of Follow", "value": ""}, {"name": "Primary Mode of Talc Exposure", "value": "Direct application to the perineum"}, {"name": "Frequency of Talc Use", "value": "More than one-third of cases and controls"}, {"name": "Effect of Talc within Specific Histologic Subtypes", "value": ""}, {"name": "Types of Talc Exposure", "value": "sanitary napkins, powdering after bathing"}, {"name": "Possible Mechanisms of Talc in Ovarian Carcinoma Etiology", "value": "entrapment of ovarian epithelium within stroma, stimulation of surface epithelium entrapment"}, {"name": "Potential Bias Sources", "value": "reporting error, selection bias, information bias"}, {"name": "Number of Subjects", "value": ""}, {"name": "Epidemiology of Ovarian Carcinoma", "value": "The text discusses the epidemiology of ovarian carcinoma and references several studies on the topic."}, {"name": "Talc and Ovarian Cancer", "value": "The text discusses the relationship between talc and ovarian cancer, referencing several studies that explore this link."}, {"name": "Other Risk Factors for Ovarian Cancer", "value": "The text mentions several other potential risk factors for ovarian cancer, such as menstrual and reproductive factors, hair dyes, and perineal talc application."}, {"name": "Study Design", "value": "Not mentioned in the text"}, {"name": "Participant Demographics", "value": "Not mentioned in the text"}, {"name": "Intervention", "value": "Not mentioned in the text"}]}, {"name": "Association of Powder Use in the Genital Area With Risk of Ovarian Cancer", "features": [{"name": "No. of Subjects", "value": "252 745; Participants in 4 studies: NHS, NHSII, SIS, and WHI-OS.; 257 044 women; 2168 cases"}, {"name": "Conclusion", "value": "There was not a statistically significant association between use of powder in the genital area and ovarian cancer, but the study may have been underpowered to identify a small increase in risk.; Genital powder use is associated with an increased risk of ovarian cancer.; No conclusion specified in the text.; Association of Powder Use in the Genital Area With Risk of Ovarian Cancer; There was no statistically significant association between self-reported use of powder in the genital area and risk of ovarian cancer.; there was not a statistically significant association between self-reported use of powder in the genital area and incident ovarian cancer; Association of Powder Use in the Genital Area With Risk of Ovarian Cancer; Association of powder use in the genital area with risk of ovarian cancer."}, {"name": "Relative Risk", "value": "1.08 (95% CI, 0.99-1.17); Hazard ratios (HRs) and 95% CIs were used to measure the association between genital use of powder and incident ovarian cancer.; 1.09 (0.98-1.20); 1.05 (0.96-1.16); 1.19 (95% CI, 1.03 to 1.37; P value for trend = .03)"}, {"name": "Length of Follow-up", "value": "Not explicitly mentioned; 0-10 or \u226510 years"}, {"name": "Cohorts Studied", "value": "The Nurses\u2019 Health Study (NHS), Nurses\u2019 Health Study II (NHSII), Sister Study (SIS), and Women\u2019s Health Initiative Observational Study (WHI-OS)"}, {"name": "Exposure Assessment Methods", "value": "The cohorts differed in how they asked participants about use of powder in the genital area"}, {"name": "Length of Follow-Up", "value": "Follow-up questionnaires were distributed every 2 years for NHS and NHSII, annually for SIS, and self-reported on annual questionnaires for WHI-OS.; Up to September 15, 2017"}, {"name": "Covariates", "value": "Age, race, education, BMI, parity, smoking status, oral contraceptive use, hormone therapy use, tubal ligation status, hysterectomy status, and menopausal status were included as potential confounders or effect modifiers."}, {"name": "Methodology", "value": "Cox proportional hazards models were used to estimate HRs and 95% CIs, with age as the primary time scale. A directed acyclic graph framework was used to select potential confounders. Study-stratified Cox models were used to control for differences across studies, and likelihood ratio tests were used to test for study heterogeneity. Proportional hazards assumptions were tested via likelihood ratio tests.; Meta-analysis, clinical trials, observational studies"}, {"name": "Subgroup Analysis", "value": "Analyses were conducted on a subgroup of women with patent reproductive tracts, hypothesized to be more susceptible to the effects of powder use in the genital area on ovarian cancer."}, {"name": "Long-term use of powder", "value": "Use of powder in the genital area for 20 years or longer"}, {"name": "Frequent use of powder", "value": "Use of powder in the genital area at least once per week or frequently between ages 10 and 13 years"}, {"name": "Sensitivity Analysis", "value": "Attempted to isolate participants who were possibly exposed to asbestos-contaminated talc by limiting analysis to women in WHI-OS and NHS, most of whom were born before 1945."}, {"name": "No. of subjects", "value": "1884; 2168 ovarian cancer cases that developed over 3.8 million person-years"}, {"name": "Relative risk", "value": "1.08; "}, {"name": "Length of follow", "value": "Not specified; long follow-up time"}, {"name": "Study design", "value": "Randomized controlled trial"}, {"name": "Age range of subjects", "value": "20-65 years"}, {"name": "Intervention type", "value": "Pharmacological"}, {"name": "Hormone Therapy", "value": "Never or Ever used"}, {"name": "Body Mass Index", "value": "<30 or \u226530"}, {"name": "No of subjects", "value": "2168"}, {"name": "Education level of participants", "value": "Highly educated"}, {"name": "Race of participants", "value": "Mostly white"}, {"name": "Obesity rate among participants", "value": "Higher among ever users of powder in genital area"}, {"name": "Length of follow-up", "value": "Not specified"}, {"name": "Tumor Invasiveness level", "value": "Invasive only"}, {"name": "Tumor location", "value": "Epithelial ovarian"}, {"name": "Length of Follow", "value": ""}, {"name": "Type of Analysis", "value": "Pooled analysis of 4 large US cohorts"}, {"name": "Factors Adjusted For", "value": "study, race/ethnicity (white, African-American, other), education (high school, some college, college graduate), body mass index (calculated as weight in kilograms divided by height in meters squared, [restricted cubic spline]), parity (0, 1, 2, 3 births), ever use of oral contraceptives, tubal ligation (yes or no), hysterectomy status (yes or no), menopausal status (premenopausal or postmenopausal), ever use of hormone therapy"}, {"name": "Confounding factors", "value": "residual confounding may still be present if the harmonized covariates did not adequately capture the relationship or if any key confounders were missing"}, {"name": "Possible recall bias", "value": "possibility for recall bias, which would result if case participants were more likely to report using powder than control participants"}, {"name": "Ethnicity and BMI of participants", "value": "All 4 cohorts included predominately white, well-educated women, approximately half of whom had a BMI of less than 25"}, {"name": "Author Affiliations", "value": "Epidemiology Branch, National\nInstitute of Environmental Health Sciences,\nResearch Triangle Park, North Carolina (O\u2019Brien,\nSandler); Department of Cancer Epidemiology, H.\nLee Moffitt Cancer Center and Research Institute,\nTampa, Florida (Tworoger); Department of\n\nEpidemiology, Harvard T.H. Chan School of Public\nHealth, Boston, Massachusetts (Tworoger);\nProgram in Epidemiology, Division of Public Health\nSciences, Fred Hutchinson Cancer Research Center,\nSeattle, Washington (Harris); Department of\nEpidemiology, School of Public Health, University of\nWashington, Seattle (Harris); Public Health Sciences\nDivision, Fred Hutchinson Cancer Research Center,\nSeattle, Washington (Anderson); Biostatistics and\n\nComputational Biology Branch, National Institute of\nEnvironmental Health Sciences, Research Triangle\nPark, North Carolina (Weinberg); Metabolic\nEpidemiology Branch, Division of Cancer\nEpidemiology and Genetics, National Cancer\nInstitute, Rockville, Maryland (Trabert);\nDepartment of Obstetrics and Gynecology,\nUniversity of Florida College of\nMedicine-Jacksonville (Kaunitz); Social and"}, {"name": "Author Contributions", "value": "Dr O\u2019Brien had full access to\nall of the data in the study and takes responsibility\nfor the integrity of the data and the accuracy of the\ndata analysis. Joint senior authors: Drs Sandler and\nWentzensen.\nConcept and design: O'Brien, Tworoger, Sandler,\nWentzensen.\nAcquisition, analysis, or interpretation of data: All\nauthors.\nDrafting of the manuscript: O'Brien, Weinberg,\nTrabert, Wentzensen.\nCritical revision of the manuscript for important\nintellectual content: O'Brien, Tworoger, Harris,\nAnderson, Trabert, Kaunitz, D'Aloisio, Sandler,\nWentzensen.\nStatistical analysis: O'Brien, Tworoger, Harris,\nTrabert.\nObtained funding: Sandler.\nAdministrative, technical, or material support:\nO'Brien, Tworoger, Harris, Kaunitz, D'Aloisio.\nSupervision: Sandler, Wentzensen."}, {"name": "Conflict of Interest Disclosures", "value": "Dr Tworoger\nreported receipt of grants from the US Department\nof Defense Ovarian Cancer Research Program\n(OCRP) and the National Institutes of Health (NIH)\nboth during the conduct of the study and outside\nthe submitted work. Dr Anderson reported receipt\nof grants from the National Heart Lung Blood\nInstitute (NHLBI) during the conduct of the study.\nDr Kaunitz reported provision of consultancy\nservices to the University of Florida, which receives\nresearch funding from companies involved with\nproducts related to contraception and treatment of\nmenopausal symptoms; personal fees for\nconsultancy services from Pfizer (injectable\ncontraception), AMAG (treatment of genital\natrophy), Mithra (contraceptive and menopausal\nhormone products), and Merck (implantable and\nvaginal ring contraception), but no companies\ninvolved with sales of powder; royalties from\nUpToDate; and funding for clinical trials\nthrough the University of Florida from\nMedicines 360 (intrauterine devices), Allergan\n(treatment of uterine fibroids), Myovant\n(treatment of uterine fibroids), and Endoceutics\n(treatment of genital atrophy). No other disclosures\nwere reported."}, {"name": "Number of subjects", "value": ""}, {"name": "Contributions", "value": "Thanks to participants and staff of participating cohorts, state cancer registries and individuals acknowledged in references"}, {"name": "References", "value": "See references 1-13"}, {"name": "Authors", "value": "Bao Y, Bertoia ML, Lenart EB, et al; Sandler DP, Hodgson ME, Deming-Halverson SL, et al; Anderson GL, Cummings SR, Freedman LS, et al; Greenland S, Pearl J, Robins JM; DerSimonian R, Laird N; Peres LC, Cushing-Haugen KL, Kobel M, et al; Xue X, Kim MY, Gaudet MM, et al; Breslow NE; Rabin RC, Hsu T; Ness RB, Cottreau C; Henderson WJ, Joslin CA, Turnbull AC, Griffiths K; Trabert B, Waterboer T, Idahl A, et al; Poole EM, White E, et al; Wentzensen N, Wacholder S."}]}, {"name": "The Association Between Talc Use and Ovarian Cancer", "features": [{"name": "Conclusion", "value": "risks for epithelial ovarian cancer from genital talc use vary by histologic subtype, menopausal status at diagnosis, Ht use, weight, and smoking. these observations suggest that estrogen and/or prolactin may play a role via macrophage activity and inflammatory response to talc.; This section of the paper does not provide any explicit conclusion.; Genital talc use is associated with an elevated epithelial ovarian cancer risk.; Association between genital talc use and epithelial ovarian cancer.; Talc use in the genital area was associated with a 33% increase in ovarian cancer risk overall while no apparent risk was associated with talc used only in non-genital areas.; There is an association between genital talc use and ovarian cancer among postmenopausal women who have ever used hormone therapy.; further study required; Overall, there is an association between genital talc use and eOc and a significant trend with increasing \u201ctalc-years\u201d of use.; The authors believe there is a case for talc carcinogenicity and re-analyses of existing data might provide confirmatory evidence."}, {"name": "No. of subjects", "value": "2,041 cases with epithelial ovarian cancer and 2,100 age- and-residence-matched controls.; 1812; Not specified"}, {"name": "Relative risk", "value": "an Or (95% ci) of 1.33 (1.16, 1.52), with a trend for increasing risk by talc-years.; 1.42 (1.13, 1.80), 1.25 (1.03, 1.53), 1.35 (0.98, 1.85), 1.52 (1.08, 2.14), 1.29 (1.11, 1.50), 1.71 (1.27, 2.30), 1.23 (0.97, 1.55), 1.35 (1.17, 1.55), 5.08 (1.32, 19.6), 1.10 (0.30, 4.12), 0.04 (0.01, 0.34), 1.38 (1.14, 1.67), 1.28 (1.06, 1.56), 1.37 (1.13, 1.66), 1.24 (1.01, 1.52), 1.28 (0.96, 1.71), 1.34 (1.15, 1.57), 1.21 (1.01, 1.45), 1.48 (1.19, 1.85), 1.35 (1.16, 1.56), 1.39 (1.16, 1.67), 1.20 (0.85, 1.70), 1.29 (1.08, 1.55), 1.35 (1.09, 1.67), 1.33 (1.15, 1.53), 1.39 (0.83, 2.33), 1.30 (1.13, 1.49), 1.31 (1.15, 1.50), 1.33 (1.16, 1.52), 1.33 (1.16, 1.53), 1.32 (1.15, 1.51), 1.32 (1.16, 1.52), 1.32 (1.15, 1.51), 1.33 (1.15, 1.52), 1.30 (1.13, 1.50), 1.32 (1.15, 1.52), 1.33 (1.16, 1.52), 1.31 (1.14, 1.52), 1.31 (1.14, 1.50), 1.33 (1.16, 1.52); 5.08 (1.32, 19.6); Not specified"}, {"name": "Length of follow-up", "value": "not specified"}, {"name": "Genital talc use definition", "value": "regular application to the genital/rectal area directly, on sanitary napkins, tampons, or underwear. to estimate \u201ctalc-years,\u201d we multiplied applications per year by years used."}, {"name": "Ovarian cancer histologic subtypes associated with talc", "value": "invasive serous and endometrioid tumors and borderline serous and mucinous tumors."}, {"name": "Factors associated with higher risk from talc use", "value": "premenopausal women, especially nonsmokers and those heavier or postmenopausal users of menopausal hormones (Ht)."}, {"name": "No. of Subjects", "value": "The study involved a total of 3,957 women residing in eastern Massachusetts and new Hampshire diagnosed with ovarian cancer between ages 18 and 80, of which 2,041 cases with epithelial tumors of ovarian, primary peritoneal, and Fallopian tube origin, including borderline malignancies were included. Controls were frequency matched to cases by 5-year age groups and region of residence.; 1551 control subjects, 549 case subjects; Not explicitly mentioned in the text."}, {"name": "Relative Risk", "value": "This information is not specified or mentioned in the text explicitly.; OR of 1.33 (95% CI = 1.16, 1.52) adjusted only for age, study center, and phase.; 1.38 (1.15, 1.65); 33%; 1.42 (1.12, 1.81)"}, {"name": "Length of Follow-up", "value": "The duration of patient follow-up is not explicitly stated."}, {"name": "Population Characteristics", "value": "The study involved women residing in eastern Massachusetts and new Hampshire who were diagnosed with ovarian cancer between ages 18 and 80. Controls were frequency matched to cases by 5-year age groups and region of residence."}, {"name": "Method of Exposure Assessment", "value": "Subjects were personally interviewed about potential ovarian cancer risk factors that occurred more than 1 year before diagnosis, for cases, and interview, for controls. Exposure assessment included estimation of talc-years and assessment of potential sources of talc exposure."}, {"name": "Statistical Methods Used", "value": "Unconditional logistic regression was used to model the odds ratio and 95% CI adjusted first for matching factors and then fully by potential confounders. Likelihood ratio tests comparing models with and without interaction terms were used to test for effect modification. Tests for trend were based on the Wald statistic using continuous variables weighted by category midpoints with zero assigned as the exposure for nonusers. Polytomous logistic regression was also used."}, {"name": "Type of Talc Powder Used", "value": "Most women reported using Johnson & Johnson's Baby Powder or Shower to Shower."}, {"name": "Age when first used genital powder", "value": "The average age women began using talc was 20.0 for cases and 19.8 for controls."}, {"name": "Trend for Frequency of Use", "value": "The trend for frequency of use was significant, but the trend for years used was flat."}, {"name": "BMI of powder users", "value": "older, heavier"}, {"name": "Presence of interaction between talc use and BMI", "value": "no"}, {"name": "Trend in association with increasing talc use", "value": "dose-response"}, {"name": "Breastfeeding categories", "value": "<4, 4\u20139, 10\u201319, >19 months"}, {"name": "Ovarian cancer risk with talc use by menopausal status", "value": ""}, {"name": "Association between talc use and ovarian cancer risk for specific subgroups", "value": ""}, {"name": "Length of Follow", "value": "Not explicitly mentioned in the text."}, {"name": "Histologic Type", "value": "Strongest dose-responses for women with invasive serous and endometrioid tumors."}, {"name": "Association with Clear Cell or Mucinous Invasive Epithelial Ovarian Cancer", "value": "Not associated with clear cell or mucinous invasive epithelial ovarian cancer regardless of menopausal status."}, {"name": "Risk by Menopausal Status and Hormone Therapy", "value": "Refer to Table 3 for the effect of tubal ligation and hysterectomy by menopausal status and hormone therapy on the association between genital talc use and ovarian cancer."}, {"name": "Length of follow", "value": "1 year; Not specified"}, {"name": "Link between powder use and asthma", "value": "may not be fully appreciated from table 2"}, {"name": "Modification of the association between talc and epithelial ovarian cancer", "value": "greater in women with no personal history of breast cancer, those who had a tubal ligation or hysterectomy, in premenopausal women, and postmenopausal women who had used Ht"}, {"name": "Talc use in postmenopausal women without Ht use and elevated risk for epithelial ovarian cancer", "value": "not been reported previously"}, {"name": "Inert particles migration", "value": "Inert particles the size of talc, present in the vagina, can migrate to the upper genital tract."}, {"name": "Dose-response", "value": "Overall, there is a significant trend for epithelial ovarian cancer risk and talc-years when nonusers are included, and the trend is even more apparent in premenopausal women with certain epithelial ovarian cancer subtypes."}, {"name": "Histologic subtypes", "value": "Histologic subtypes of epithelial ovarian cancer more likely to be associated with talc include serous and mucinous borderline tumors and invasive serous and endometrioid tumors."}, {"name": "Associated factors", "value": "['Perineal talc exposure', 'Chronic pelvic inflammation', 'NSAIDs']"}, {"name": "Study references", "value": "['Cralley LJ, et al.', 'Graham J, Graham R', 'Henderson WJ, et al.', 'Cramer DW, et al.', 'Purdie D, et al.', 'Chang S, Risch HA', 'Cramer DW, et al.', 'Wong C, et al.', 'Ness RB, et al.', 'Mills PK, et al.', 'Merritt MA, et al.', 'Wu AH, et al.', 'Rosenblatt KA, et al.', 'Langseth H, et al.', 'Gates MA, et al.', 'Terry KL, et al.; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium', 'Vitonis AF, et al.', 'McCluggage WG']"}, {"name": "Validation Method", "value": "Semi-quantitative food frequency questionnaire - comparison with a 1-year diet record"}, {"name": "Bias Analysis", "value": "Applying Quantitative Bias Analysis to Epidemiologic Data"}, {"name": "Hormonal Risk Factors", "value": "Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women"}]}, {"name": "Risk factors for ovarian cancer a case-control study", "features": [{"name": "Conclusion", "value": "High gravidity, hysterectomy, female sterilisation and oral contraceptive use were associated with a reduced risk of ovarian cancer. Infertility and late age at menopause were associated with an increase in risk.; Increased risk of ovarian cancer with increasing duration of unprotected intercourse among sexually active women after adjustment for gravidity. Women who had never used contraception had about twice the risk of ovarian cancer compared to all other sexually active women. Ever having used oral contraception and having been sterilised were associated with a statistically significantly reduced risk of ovarian cancer. No other method was associated with significantly elevated risk.; Women who used oral contraceptives had a lower risk of ovarian cancer than those who had never used them, the risk being lowest in those who had first used oral contraceptives under the age of 25 years. Women who had stopped using oral contraceptives more than ten years previously had a statistically significant reduced risk of 0.3 compared to women who had never used them. Women both under the age and over the age of 40 years had a reduced risk of ovarian cancer associated with oral contraceptive use, but the reduction was greater in the younger women. Gravid and nulligravid women who had used oral contraceptives had a reduced risk of ovarian cancer.; Women who reported hysterectomy, with or without unilateral oophorectomy, had a much reduced risk; Nulligravid women have an increased risk of ovarian cancer while risk decreases as number of pregnancies increases. Greater number of incomplete pregnancies had lower risk, although trend was not significant. Infertility is a risk factor for ovarian cancer. Age at first pregnancy not associated with risk. Women having first pregnancy after age of 35 years have higher risk compared to women having first pregnancy at earlier ages and nulligravid women.; Our finding of no overall relationship between hormone\nreplacement therapy and ovarian cancer supports those of other\ninvestigators (Newhouse et al., 1977; Hildreth et al., 1981; Weiss\net al., 1982). An increased risk associated with the therapy was\nfound among women who reported hysterectomy, but the\nfinding was based on very few cases and may have been due to\nchance. We did not find an increased risk associated with\noestrogen therapy for any particular tumour types as suggested\nby Cramer et al. (1981) and Weiss et al. (1982).\n; Various studies on ovarian cancer in different countries."}, {"name": "No. of subjects", "value": "235 women with histologically diagnosed epithelial ovarian cancer and 451 controls; Not specified; Not specified"}, {"name": "Relative risk", "value": "Variable; 0.9 - 2.6, 0.7 - 2.3, 0.8 - 2.0, 0.4 - 1.5, 0.4 - 1.4, 0.3 - 1.1, 0.2 - 1.0, 0.2, 0.6, 0.1, 1.3, 1.1, 1.9, 1.2, 1.5, 1.3, 3.2, 1.1, 0.9, 1.0, 2.4, 2.4, 5.0"}, {"name": "Length of follow up", "value": "between October 1978 and February 1983"}, {"name": "Risk factors", "value": "Menstrual characteristics, reproductive and contraceptive history and history of exposure to various environmental factors"}, {"name": "Tumour type", "value": "Described as serous in 101 (43%) cases, mucinous in 38 (15%) cases, endometrioid in 52 (22%) cases and clear cell in 12 (5%) cases. Mixed and undifferentiated types of epithelial tumours accounted for the remaining 32 (14%) cases."}, {"name": "Length of follow-up", "value": "Not specified"}, {"name": "Method(s) of contraception", "value": "Oral contraception, sterilisation"}, {"name": "Infertility/subfertility", "value": "16 cases and 12 controls had never conceived"}, {"name": "Age distribution", "value": "Cases: 20-34 (5.5%), 35-44 (11.5%), 45-54 (37.0%), 55-64 (46.0%). Controls: 20-34 (7.3%), 35-44 (16.6%), 45-54 (34.6%), 55-64 (41.5%)."}, {"name": "No. of Subjects", "value": "197"}, {"name": "Relative Risk", "value": "1.oa; 3.9"}, {"name": "Length of Follow", "value": "Not specified"}, {"name": "Methods of Contraception", "value": "There is a table showing relative risks for ovarian cancer associated with the use of different methods of contraception (diaphragm, sheath, intrauterine device, oral contraception, partner with vasectomy, female sterilization, other methods)."}, {"name": "Age Related Risks", "value": "There is a table showing the relative risks for ovarian cancer associated with age at menarche and age at natural menopause. Risk increased the later the age at natural menopause. Women having their menopause at the age of 50 years or later had nearly three times the risk of women who were menopausal before the age of 45 years. There was no trend in risk with age at menarche."}, {"name": "Contraceptive Duration", "value": "There is a table showing relative risks for ovarian cancer associated with duration of use of contraception by gravidity. The risks decreased as duration of use increased although, among those who had ever used such contraceptives, the trend was not significant."}, {"name": "Age at Menarche", "value": "Data missing for 3 cases and 3 controls"}, {"name": "Age at Menopause", "value": "Data missing for 2 cases and 1 control"}, {"name": "Duration of Ovulation", "value": "Estimated as the months from menarche to diagnosis/interview or to menopause, whichever came first, minus the total months of anovulation due to pregnancy and oral contraceptive use. Women who reported a hysterectomy were excluded from these analyses as it was unknown if or when they had stopped ovulating. For all women combined, there was a strong trend of increasing risk the longer the duration of ovulation (X2 (trend) = 17.8, P <0.001)"}, {"name": "Use of Hormone Replacement Therapy", "value": "A small but non-significantly increased risk of ovarian cancer associated with never having received HRT"}, {"name": "Talc Use", "value": "Women who reported using talc more than once a week or daily had higher risks of ovarian cancer than women who reported less frequent use"}, {"name": "Length of follow", "value": "Not specified"}, {"name": "Factors related to ovarian cancer", "value": "Gravidity, Unprotected intercourse (months), Oral contraceptive use, Ever sterilized, Age at natural menopause, Hysterectomy, Frequency of talc use in the genital area"}, {"name": "Statistical significance", "value": "X2 for trend = 12.3 P <0.001,  X2 for trend = 4.4 P < 0.05, 7.8 P <0.05, 6.5 P<0.05, 8.2 P <0.01, X2 for trend = 3.80, P = 0.05"}, {"name": "95% CI", "value": "1.1- 14.2"}, {"name": "Association between contraception and ovarian cancer", "value": "No association found between contraception and ovarian cancer. Female sterilisation and use of oral contraception associated with a significant reduction in risk and no method was associated with a significant increase in risk. The associations remained after adjusting for gravidity and duration of unprotected intercourse."}, {"name": "Association between breastfeeding and ovarian cancer", "value": "No evidence found that the longer a woman had breastfed the lower her risk of ovarian cancer. The highest risk was found in those who had breastfed longest."}, {"name": "Association between age at menarche and ovarian cancer", "value": "No association found between age at menarche and risk."}, {"name": "Association between age at natural menopause and ovarian cancer", "value": "The later the age at natural menopause the greater the risk."}, {"name": "Association between hysterectomy and ovarian cancer", "value": "A lower frequency of hysterectomy among cases compared to controls has been reported from several other studies. Following hysterectomy with ovarian conservation, reduced ovarian function or ovarian failure occurs in a proportion of women, due possibly to the blood supply to the ovaries being compromised. If at hysterectomy a woman's ovaries look diseased, it is likely that they are removed. If the diseased ovaries were precancerous, those women who might otherwise have developed ovarian cancer do not."}, {"name": "Association between female sterilisation and ovarian cancer", "value": "Female sterilisation was also associated with a low risk of ovarian cancer. The menstrual disturbance that many women experience after sterilisation may reflect changed ovarian function due to damage to the vascular supply to the ovaries."}, {"name": "Association between duration of ovulation and ovarian cancer", "value": "Risk increased the longer the duration of ovulation."}, {"name": "Relative risk & length of follow", "value": ""}, {"name": "Frequency of talc use among cases", "value": "More than once a week or daily"}, {"name": "Funding source", "value": "The Imperial Cancer Research Fund"}, {"name": "Number of subjects", "value": ""}, {"name": "Reproductive Factors", "value": "Events of reproductive life and noncontraceptive estrogen use are associated with ovarian cancer."}, {"name": "Occupation", "value": "Occupation is not discussed."}, {"name": "Personal and Environmental Characteristics", "value": "Personal and environmental characteristics related to epithelial ovarian cancer including reproductive and menstrual events and oral contraceptive use are studied."}]}, {"name": "Risk factors for ovarian cancer a case-control study", "features": [{"name": "Conclusion", "value": "High gravidity, hysterectomy, female sterilisation and oral contraceptive use were associated with a reduced risk of ovarian cancer. Infertility and late age at menopause were associated with an increase in risk.; Increased risk of ovarian cancer with increasing duration of unprotected intercourse among sexually active women after adjustment for gravidity. Women who had never used contraception had about twice the risk of ovarian cancer compared to all other sexually active women. Ever having used oral contraception and having been sterilised were associated with a statistically significantly reduced risk of ovarian cancer. No other method was associated with significantly elevated risk.; Women who used oral contraceptives had a lower risk of ovarian cancer than those who had never used them, the risk being lowest in those who had first used oral contraceptives under the age of 25 years. Women who had stopped using oral contraceptives more than ten years previously had a statistically significant reduced risk of 0.3 compared to women who had never used them. Women both under the age and over the age of 40 years had a reduced risk of ovarian cancer associated with oral contraceptive use, but the reduction was greater in the younger women. Gravid and nulligravid women who had used oral contraceptives had a reduced risk of ovarian cancer.; Women who reported hysterectomy, with or without unilateral oophorectomy, had a much reduced risk; Nulligravid women have an increased risk of ovarian cancer while risk decreases as number of pregnancies increases. Greater number of incomplete pregnancies had lower risk, although trend was not significant. Infertility is a risk factor for ovarian cancer. Age at first pregnancy not associated with risk. Women having first pregnancy after age of 35 years have higher risk compared to women having first pregnancy at earlier ages and nulligravid women.; Our finding of no overall relationship between hormone\nreplacement therapy and ovarian cancer supports those of other\ninvestigators (Newhouse et al., 1977; Hildreth et al., 1981; Weiss\net al., 1982). An increased risk associated with the therapy was\nfound among women who reported hysterectomy, but the\nfinding was based on very few cases and may have been due to\nchance. We did not find an increased risk associated with\noestrogen therapy for any particular tumour types as suggested\nby Cramer et al. (1981) and Weiss et al. (1982).\n; Various studies on ovarian cancer in different countries."}, {"name": "No. of subjects", "value": "235 women with histologically diagnosed epithelial ovarian cancer and 451 controls; Not specified; Not specified"}, {"name": "Relative risk", "value": "Variable; 0.9 - 2.6, 0.7 - 2.3, 0.8 - 2.0, 0.4 - 1.5, 0.4 - 1.4, 0.3 - 1.1, 0.2 - 1.0, 0.2, 0.6, 0.1, 1.3, 1.1, 1.9, 1.2, 1.5, 1.3, 3.2, 1.1, 0.9, 1.0, 2.4, 2.4, 5.0"}, {"name": "Length of follow up", "value": "between October 1978 and February 1983"}, {"name": "Risk factors", "value": "Menstrual characteristics, reproductive and contraceptive history and history of exposure to various environmental factors"}, {"name": "Tumour type", "value": "Described as serous in 101 (43%) cases, mucinous in 38 (15%) cases, endometrioid in 52 (22%) cases and clear cell in 12 (5%) cases. Mixed and undifferentiated types of epithelial tumours accounted for the remaining 32 (14%) cases."}, {"name": "Length of follow-up", "value": "Not specified"}, {"name": "Method(s) of contraception", "value": "Oral contraception, sterilisation"}, {"name": "Infertility/subfertility", "value": "16 cases and 12 controls had never conceived"}, {"name": "Age distribution", "value": "Cases: 20-34 (5.5%), 35-44 (11.5%), 45-54 (37.0%), 55-64 (46.0%). Controls: 20-34 (7.3%), 35-44 (16.6%), 45-54 (34.6%), 55-64 (41.5%)."}, {"name": "No. of Subjects", "value": "197"}, {"name": "Relative Risk", "value": "1.oa; 3.9"}, {"name": "Length of Follow", "value": "Not specified"}, {"name": "Methods of Contraception", "value": "There is a table showing relative risks for ovarian cancer associated with the use of different methods of contraception (diaphragm, sheath, intrauterine device, oral contraception, partner with vasectomy, female sterilization, other methods)."}, {"name": "Age Related Risks", "value": "There is a table showing the relative risks for ovarian cancer associated with age at menarche and age at natural menopause. Risk increased the later the age at natural menopause. Women having their menopause at the age of 50 years or later had nearly three times the risk of women who were menopausal before the age of 45 years. There was no trend in risk with age at menarche."}, {"name": "Contraceptive Duration", "value": "There is a table showing relative risks for ovarian cancer associated with duration of use of contraception by gravidity. The risks decreased as duration of use increased although, among those who had ever used such contraceptives, the trend was not significant."}, {"name": "Age at Menarche", "value": "Data missing for 3 cases and 3 controls"}, {"name": "Age at Menopause", "value": "Data missing for 2 cases and 1 control"}, {"name": "Duration of Ovulation", "value": "Estimated as the months from menarche to diagnosis/interview or to menopause, whichever came first, minus the total months of anovulation due to pregnancy and oral contraceptive use. Women who reported a hysterectomy were excluded from these analyses as it was unknown if or when they had stopped ovulating. For all women combined, there was a strong trend of increasing risk the longer the duration of ovulation (X2 (trend) = 17.8, P <0.001)"}, {"name": "Use of Hormone Replacement Therapy", "value": "A small but non-significantly increased risk of ovarian cancer associated with never having received HRT"}, {"name": "Talc Use", "value": "Women who reported using talc more than once a week or daily had higher risks of ovarian cancer than women who reported less frequent use"}, {"name": "Length of follow", "value": "Not specified"}, {"name": "Factors related to ovarian cancer", "value": "Gravidity, Unprotected intercourse (months), Oral contraceptive use, Ever sterilized, Age at natural menopause, Hysterectomy, Frequency of talc use in the genital area"}, {"name": "Statistical significance", "value": "X2 for trend = 12.3 P <0.001,  X2 for trend = 4.4 P < 0.05, 7.8 P <0.05, 6.5 P<0.05, 8.2 P <0.01, X2 for trend = 3.80, P = 0.05"}, {"name": "95% CI", "value": "1.1- 14.2"}, {"name": "Association between contraception and ovarian cancer", "value": "No association found between contraception and ovarian cancer. Female sterilisation and use of oral contraception associated with a significant reduction in risk and no method was associated with a significant increase in risk. The associations remained after adjusting for gravidity and duration of unprotected intercourse."}, {"name": "Association between breastfeeding and ovarian cancer", "value": "No evidence found that the longer a woman had breastfed the lower her risk of ovarian cancer. The highest risk was found in those who had breastfed longest."}, {"name": "Association between age at menarche and ovarian cancer", "value": "No association found between age at menarche and risk."}, {"name": "Association between age at natural menopause and ovarian cancer", "value": "The later the age at natural menopause the greater the risk."}, {"name": "Association between hysterectomy and ovarian cancer", "value": "A lower frequency of hysterectomy among cases compared to controls has been reported from several other studies. Following hysterectomy with ovarian conservation, reduced ovarian function or ovarian failure occurs in a proportion of women, due possibly to the blood supply to the ovaries being compromised. If at hysterectomy a woman's ovaries look diseased, it is likely that they are removed. If the diseased ovaries were precancerous, those women who might otherwise have developed ovarian cancer do not."}, {"name": "Association between female sterilisation and ovarian cancer", "value": "Female sterilisation was also associated with a low risk of ovarian cancer. The menstrual disturbance that many women experience after sterilisation may reflect changed ovarian function due to damage to the vascular supply to the ovaries."}, {"name": "Association between duration of ovulation and ovarian cancer", "value": "Risk increased the longer the duration of ovulation."}, {"name": "Relative risk & length of follow", "value": ""}, {"name": "Frequency of talc use among cases", "value": "More than once a week or daily"}, {"name": "Funding source", "value": "The Imperial Cancer Research Fund"}, {"name": "Number of subjects", "value": ""}, {"name": "Reproductive Factors", "value": "Events of reproductive life and noncontraceptive estrogen use are associated with ovarian cancer."}, {"name": "Occupation", "value": "Occupation is not discussed."}, {"name": "Personal and Environmental Characteristics", "value": "Personal and environmental characteristics related to epithelial ovarian cancer including reproductive and menstrual events and oral contraceptive use are studied."}]}]